Legal Bay Provides 2026 Mass Tort Litigation Update on Talc, Depo-Provera, and Cartiva Claims
Pre-settlement funding provider Legal Bay LLC has released its 2026 outlook on three major mass tort cases it continues to monitor and fund, covering talc ovarian cancer litigation, Depo-Provera brain tumor claims, and the emerging Cartiva toe implant lawsuits.
As reported by PR Newswire, Legal Bay CEO Chris Janish said talc litigation against Johnson & Johnson has "clearly reached a mature phase," with multiple bankruptcy attempts dismissed and cases returned to traditional proceedings. The company believes 2026 may finally bring a meaningful global resolution, noting that J&J's stock price has nearly doubled from litigation-driven lows.
The Depo-Provera docket, which alleges the injectable contraceptive caused meningioma brain tumors, is moving into a bellwether testing phase. Courts are increasingly scrutinizing litigation funding agreements in these cases for disclosure. Janish acknowledged that "disclosure requirements are becoming a larger part of complex litigation."
The third area of focus — Cartiva synthetic cartilage toe implants — represents an early-stage medical device docket involving reported implant failures and revision surgeries. Legal Bay noted growing plaintiff interest in this emerging litigation.
The company emphasized that its non-recourse funding agreements do not interfere with attorney-client relationships or settlement authority, and that clients owe nothing if they do not secure a recovery.
